I'm posting information about this trial because it has many U.K. locations and a number in France and Italy.
This is a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Rituximab for Previously Treated Chronic Lymphocytic Leukemia.
Eligible patients will be randomized with a 1:1 ratio into 1 of the 2 treatment arms to receive either Idelalisib or placebo. All subjects will be administered rituximab. Subjects who are tolerating primary study therapy but experience definitive CLL progression are eligible to receive active Idelalisib therapy in the extension study, GS-US-312-0117.
LINK see locations on this page...